EXHIBIT 99.2

FOR IMMEDIATE RELEASE
Company:                                                       Media Relations:
LifePoint, Inc.                                                The Blaine Group
(909) 466-8047 x 400                                           (310) 360-1499
e-mail:  lifepoint@LFPT.com
Website: www.lifepointinc.com
Contact: Linda H. Masterson, CEO & Pres.

LIFEPOINT, INC. ANNOUNCES OVER $8 MILLION FUNDING AND CONVERSION OF
CONVERTIBLE PREFERRED STOCK

ONTARIO, Calif. -March 14, 2000- LifePoint, Inc. (LFPT), a developer of rapid,
non-invasive testing products using saliva, announced today that it filed a
Current Report on Form 8-K disclosing that the Company had completed at least
$8 million of long-term funding through a private placement pursuant to
Regulation D of the Securities Act of 1933.

In the private placement the Company offered units, each unit consisting of
2500 shares of LifePoint Common Stock and 2500 $3 warrants to purchase
LifePoint Common Stock, at $5,000 per unit.  The warrants may not be exercised
prior to September 14, 2000 and the shares included in the units are restricted
securities for at least one year.  LifePoint has previously announced that it
would require an additional $4.5 million to bring the first product to market;
therefore, this offering will allow LifePoint to complete the product
development and bring the first product to market, and provide LifePoint with
operating funds for several quarters past initiation of revenues.

Additionally, LifePoint also disclosed the mandatory conversion of the
remaining Series A Preferred Stock effective March 24, 2000, which $6 million
offering had funded the company's final development efforts from January 1999
through the completion of the prototype instrument the second quarter of 2000.
The redemption was required because the average market price of the Company's
Common Stock was over $4.00 during a 30 day period.  The previously
non-converted shares of the Series A Preferred Stock are substantially owned
by several long-term investors in LifePoint.  Over 53% of the remaining shares
are owned by The General Conference Corporation of  Seventh-day Adventists,
who have participated in every financing round LifePoint has completed since
1997, including the current private placement.  The mandatory conversion of
the remaining shares of the Series A Preferred Stock will add 8,547,500 shares
of LifePoint Common Stock to the outstanding shares.

On a fully-diluted basis, with the current private placement and the conversion
of the Preferred Series A Stock, LifePoint Common Stock (now the only issued
stock of the corporation) is distributed as follows:  28% is held by insiders
(management and directors) and institutions own 31% of LifePoint.  The General
Conference Corporation of  Seventh-day Adventists owns 48% of the institutional
position; therefore, the 43% of the Common Stock is highly affiliated or held
by insiders and 23% is restricted for one year.

LifePoint, Inc. is a late development stage company designing a unique product
that will provide immediate, on-site diagnostic results without the need to
take blood or urine.  LifePoint is focused on the commercialization of the
flow immunosensor technology licensed from the Naval Research Laboratories.

This patented technology, when used in conjunction with saliva as a
non-invasive test specimen using the Company's proprietary collection
technology, will allow LifePoint to develop a broadly applicable non-invasive,
rapid, on-site diagnostic test system. The LifePointT product could be used for
rapid diagnostic testing, for screening, and therapeutic drug monitoring in
non-medical environments such as the workplace, home health care, ambulances,
pharmacies, and law enforcement.  The first product under development is for
the simultaneous detection of drugs of abuse and alcohol.  The market
potential for this product is estimated to be $750 million and growing to
over $1 billion by 2002.  Marketing to the non-medical markets is anticipated
to begin no earlier than the fourth quarter of 2000.

For more information on LifePoint, Inc. visit www.lifepointinc.com or call
(909) 466-8047 x 400.

This press release contains forward-looking statements regarding future events
and the future performance of LifePoint, Inc. that involve risks and
uncertainties that could cause actual results to differ materially. These
risks include, but are not limited to, the completion of product development,
the need for additional funding, the initiation and completion of clinical
trials and dependence on third parties for clinical testing and marketing.
These risks are described in further detail in the Company's reports filed
with the Securities and Exchange Commission.

LifePoint is a trademark of LifePoint, Inc.